|
|
Hematology, Oncology and
Bone Marrow Transplantation
Research Funding
(listed alphabetically by Principal Investigator)
An Open-Label, Noncomparative Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc.
Amount: Per patient enrolled
Term: 1999-2005
An Open-Label, Noncomparative Study of FK463 for the Treatment of Invasive Aspergillosis
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc.
Amount: Per patient enrolled
Term: 1999-2005
A Phase II, Open-Label Study of Clofarex in Pediatric Patients with Refractory or Relapsed Acute Myelogenous Leukemia
Principal Investigator: Edythe A. Albano, MD
Source: Ilex Products
Amount: Per patient enrolled
Term: 2003-2005
Postgraduate Training in Pediatric Oncology
Principal Investigator: Robert L. Garcea, MD
Source: National Institutes of Health, National Cancer Institute - CA8208601
Amount: $999,879
Term: 2000-2005
Mechanisms in Papovavirus Assembly
Principal Investigator: Robert L. Garcea, MD
Source: National Institutes of Health, National Cancer Institute - 2R01 CA37667-21
Amount: $235,000/yr
Term: 2003-2008
Development of a Next Generation Human Papillomavirus Vaccine
Co-Principal Investigators: Robert L. Garcea, MD, and Richard Schlegel, MD, PhD
Source: National Cancer Institute
Amount: $600,000/yr (current funding for GMP Production)
Term: 2001-present
PCR Analysis of Tumor and Normal DNA
Principal Investigator: Richard L. Garcea, MD
Source: National Cancer Institute - 40054-NV
Amount: $22,000
Term: 2004-2005
Novel Therapeutic Vaccines for Acute and Persistent Papillomavirus Infections
Principal Investigator: Richard L. Garcea, MD
Source: Bill and Melinda Gates Foundation, Grand Challenges in Global Health - 37881
Amount: $3,540,000
Term: 2005-2010
Postgraduate Training in Pediatric Oncology
Principal Investigator: Richard L. Garcea, MD
Source: National Institutes of Health, National Cancer Institute - T32-CA82086-05
Amount: $231,396/yr
Term: 2000-2005
MEKK2 KO Defines Hematopoietic Cell Signal Function
Principal Investigator: Timothy P. Garrington, MD
Source: National Institutes of Health, National Cancer Institute, K08 Award (Mentored Clinical Scientist Development Award) - CA85276-03
Amount: $662,500
Term: 2000-2005
American Society of Hematology Scholar Award in Clinical/Translational Research
Principal Investigator: Neil Goldenberg, MD
Source: CU Foundation - Project 2580553
Amount: $150,000
Term: 2005-present
Hemophilia and Thrombosis Research Society Thrombosis Studies Aware
Principal Investigator: Neil Goldenberg, MD
Source: CU Foundation - Program 37391
Amount: $35,000
Term: 2005
National Hemophilia Foundation Clinical Fellowship Award
Principal Investigator: Neil Goldenberg, MD
Faculty: Marilyn Manco-Johnson, MD
Source: UCD Office of Grants and Contracts - Project 200405-093
Amount: $200,000
Term: 2004-2007
K12 Clinical Oncology Scholars Award
Principal Investigator: Lia Gore, MD,
Source: National Institutes of Health - CA86913
Amount: $525,000
Term: 2001-2006
Phase I Drug Development Program
Co-Principal Investigators: Lia Gore, MD, and Gail S. Eckhardt, MD
Source: National Institutes of Health, National Cancer Institute -5U01 CA099176-03
Amount: $1,622,852
Term: 2003-2008
In Vitro and In Vivo Characterization of the Histone Deacetylase Inhibitors SAHA and MS-275 Alone, and in Combination with Other Agents in Pediatric Acute Lymphoblastic Leukemia
Principal Investigator: Lia Gore, MD
Source: Cancer League of Colorado
Amount: $26,500
Term: 2005-2006
Experimental Therapeutics Program
Principal Investigator: Lia Gore, MD
Source: The Children's Hospital Research Institute
Amount: $214,000/yr
Term: 2004-2008
Evaluation of the Anti-Tumor Activity of SAHA Administered in Combination with 5-Azacytidine using In Vitro and In Vivo Models of Pediatric Acute Lymphocytic Leukemia with Poor Prognosis
Principal Investigator: Lia Gore, MD
Source: Merck & Co, Inc.
Amount: $60,062
Term: 2005-2006
The Mer Tyrosine Kinase as a Potential Therapeutic Target in Lymphoblastic Leukemias
Principal Investigator: Douglas K. Graham MD, PhD
Source: Cancer League of Colorado - 63066647
Amount: $30,000
Term: 2005-2006
The Mer Oncogene and Merstatin: a Novel High Impact Therapeutic Target
Principal Investigator: Douglas K. Graham, MD, PhD
Source: UCD Technology Transfer Proof of Concept Award
Amount: $100,000
Term: 2005-2006
An Animal Model of TRALI
Principal Investigator: Christopher C. Silliman, MD, PhD
Source: National Institutes of Health - HL-59355-05
Amount: $2,402,388
Term: 1999-2007
Project II: The Role of Neutral Lipophilic Compounds from Stored Blood in Pulmonary Endothelial Activation
Principal Investigator: Christopher C. Silliman, MD, PhD
Source: National Institutes of Health, National Institute General Medical Sciences
Amount: $1,615,579
Term: 2005-2010
Lymphotropic Polyomavirus: Natural History and Potential Role in Lymphoid Cancer in Humans
Principal Investigator: Michael Wang, MD
Source: American Cancer Society, University of Colorado Cancer Center Seed Grant
Amount: $20,000
Term: 2005
Lymphotropic Polyomavirus Infection and Its Potential Role in Lymphoid Cancer in Humans
Principal Investigator: Michael Wang, MD
Source: National Institutes of Health, National Centers for Research Resources, UCD Pediatric Clinical Translational Research Center, General Clinical Research Centers Program - M01 RR00069
Amount: $22,896/yr
Term: 2005-2006
2003-2004
An Open-Label, Noncomparative Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc.
Amount: Per patient enrolled
Term: 1999-present
An Open-Label, Noncomparative Study of FK463 for the Treatment of Invasive Aspergillosis
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc.
Amount: Per patient enrolled
Term: 1999-present
A Phase II, Open-Label Study of Clofarex in Pediatric Patients with Refractory or Relapsed Acute Myelogenous Leukemia
Principal Investigator: Edythe A. Albano, MD
Source: Ilex Products
Amount: Per patient enrolled
Term: 2003-present
Evaluation of Effects of CP-34,131 on Neutrophil Function
Principal Investigator: Daniel R. Ambruso, MD
Source: Pfizer, Inc.
Amount: $2,000/yr
Term: 2001-2012
Comparative Growth Inhibition by Selectively Targeting PK-C zeta in Glioblastoma and Normal Astrocytes.
Principal Investigator: Nicholas K. Foreman, MD, ChB
Source: American Cancer Society
Amount: $20,000/yr
Term: 2001-present
Microbial Pathogenesis and Host Responses to Infection
Principal Investigator: Randall K. Holmes, MD, PhD
Training Faculty: Robert L. Garcea, MD
Source: National Institutes of Health - CAI 07537
Amount: $380,515
Term: 1999-2004
Predoctoral Training Program in Molecular Biology
Principal Investigator: Charles McHenry, PhD
Training Faculty: Robert L. Garcea, MD
Source: National Institutes of Health - GM08730-01
Amount: $88,328
Term: 1999-2004
Postgraduate Training in Pediatric Oncology
Principal Investigator: Robert L. Garcea, MD
Source: National Institutes of Health, National Cancer Institute - CA8208601
Amount: $999,879
Term: 2000-2005
MEKK2 KO Defines Hematopoietic Cell Signal Function
Principal Investigator: Timothy P. Garrington, MD
Source: National Institutes of Health, National Cancer Institute, K08 Award (Mentored Clinical Scientist Development Award) - CA85276-03
Amount: $662,500
Term: 2000-2005
Children's Oncology Group
Principal Investigator: Roger Giller, MD
Source: University of Colorado, Department of Pediatrics
Amount: $175,640
Term: 1980-2003
Multicenter Investigation of Induction of Stable Mixed Chimerism After Bone Marrow Transplantation from HLA-Identical Donors for Sickle Cell Disease
Principal Investigator: Roger Giller, MD
Faculty: Rachelle Nuss, MD
Source: National Institutes of Health U01 - HL-068091
Amount: $44,400
Term: 2001-2006
K12 Clinical Oncology Scholars Award
Principal Investigator: Lia Gore, MD
Source: National Institutes of Health - CA86913
Amount: $871,500
Term: 2001-2008
Orphan Drug Act
Principal Investigator: Lia Gore, MD
Source: US Food and Drug Administration
Amount: $136,862
Term: 2002-2003
Experimental Therapeutics Program
Principal Investigator: Lia Gore, MD
Source: Morgan Adams Memorial Neuro-Oncology Research Fund
Amount: $50,000/yr
Term: 2002-present
Brent Eley Research Fellow
Principal Investigator: Douglas K. Graham, MD, PhD
Source: The Children's Hospital Research Institute Scholar Award
Term: 2001-2003
Expression of Mer in Pediatric Leukemia Patient Samples
Principal Investigator: Douglas K. Graham, MD, PhD
Source: Children's Cancer Research Fund
Term: 2002-2003
Butterfly Program
Principal Investigator: Brian S. Greffe, MD
Source: Children's Hospice International Grant
Amount: $100,000
Term: 2002-2004
K08 B Cell Expansion After Dendritic Cell Immunization
Principal Investigator: Michael B. Jordan, MD
Source: National Institutes of Health - K08 AI50802
Amount: $360,000
Term: 2002-2005
An Animal Model of Hemophagocytic Lymphohistiocytosis
Principal Investigator: Michael B. Jordan, MD
Source: The Histiocytosis Association of America
Amount: $60,000
Term: 2002-2004
Suicide Liposomes for Treatment of Immune-Mediated Anemia in Dogs
Co-Principal Investigators: Michael B. Jordan, MD, and Steven Dow, DVM, PhD
Source: The Morris Foundation
Amount: $120,000
Term: 2002-2005
Abnormal Hemoglobin Testing and Counseling Services
Principal Investigator: Kathryn L. Hassell, MD
Faculty: Rachelle Nuss, MD
Source: Wyoming Department of Health
Amount: $4,880
Term: 2001-2003
Sickle Cell Center Contract for Newborn Screening Follow-Up
Principal Investigator: Kathryn L. Hassell, MD
Faculty: Rachelle Nuss, MD
Source: Colorado Department of Health
Amount: $175,164
Term: 2001-2003
Teaching and Interpretation of Hemoglobin Electrophoresis
Principal Investigator: Kathryn L. Hassell, MD
Faculty: Rachelle Nuss, MD
Source: University of Colorado Hospital Laboratory
Amount: $10,000
Term: 2001-2003
Early Hearing Detection and Intervention: Tracking, Research and Integration with Other Newborn Screening Programs
Principal Investigator: Peter A. Lane, MD
Faculty: Rachelle Nuss, MD
Source: Centers for Disease Control and Prevention - 02-00556
Amount: $115,000
Term: 2001-2004
Develop, Implement and Ensure Comprehensive Hemophilia Evaluation and Management of Clinics for Federal Region VIII
Principal Investigator: Marilyn Manco-Johnson, MD
Source: Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Bureau - MC00008-01
Amount: $499,684
Term: 2001-2003
Integrating Prevention Services for Persons with Bleed and Clotting Disorders
Principal Investigator: Marilyn Manco-Johnson, MD
Source: Centers for Disease Control and Prevention - CCU8200552-01
Amount: $184,441
Term: 2001-2003
Preventing Complications in Persons with Hemophilia (Mountain States Regional Hemophilia Center)
Principal Investigator: Marilyn Manco-Johnson, MD
Source: Centers for Disease Control and Prevention - CCU813109-06
Amount: $323,778
Term: 2001-2003
Prevention of Joint Disease in Preschool Children with Hemophilia
Principal Investigator: Marilyn Manco-Johnson, MD
Source: Centers for Disease Control and Prevention - CCU812106-07
Amount: $211,114
Term: 2001-2003
Provide Education, Community Outreach and Direct Patient Care for Hemophilia and Related Bleeding Disorders
Principal Investigator: Marilyn Manco-Johnson, MD
Source: State of Colorado
Amount: $231,625
Term: 2001-2003
The Acute Chest Syndrome in Sickle Cell Anemia: The Role of the Neutrophil
Co-Principal Investigators:Rachelle Nuss, MD, and Christopher Silliman, MD, PhD
Source: Pediatric General Clinical Research Center - Pilot
Amount: $90,000
Term: 2002-2003
An Animal Model of TRALI
Principal Investigator: Christopher Silliman, MD, PhD
Source: National Institutes of Health - HL-59355-05
Amount: $2,402,388
Term: 1999-2007
Project IX: Lipid Chemistry CORE, PO-A: The Role of Lipids Generated During Blood Storage in Trauma-Induced Multiple Organ Failure
Principal Investigator: Christopher Silliman, MD, PhD
Source: National Institutes of Health - GM49222-12
Amount: $3,346,299
Term: 2001-2004
2001-2002
An Open-Label, Noncomparative Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc.
Amount: Per patient enrolled
Term: 1999-present
An Open-Label, Noncomparative Study of FK463 for the Treatment of Invasive Aspergillosis
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc.
Amount: Per patient enrolled
Term: 1999-present
A Phase I Study to Determine the Safety and Pharmacokinetics of FK463 in Febrile Neutropenic Pediatrics
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc.
Amount: Per patient enrolled
Term: 1999-2001
A Phase III, Double-Blind, Randomized Comparison of Two Administration Schedules of Leridistim (SC-70935) vs. G-CSF in the Prevention of Secondary Febrile Neutropenia in Pediatric Cancer Patients
Principal Investigator: Edythe A. Albano, MD
Source: GD Searle & CO
Amount: Per patient enrolled
Term: 1999-2001
A Phase III, Randomized, Double-Blind, Comparative Trial of FK463 vs. Fluconazole for Prophylaxis of Fungal Infections in Patients Undergoing a Hematopoietic Stem Cell Transplant
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc
Amount: Per patient enrolled
Term: 1999-2001
Evaluation of Neutrophil Function During Administration of G-CSF to Normal Volunteers
Principal Investigator: Daniel R. Ambruso, MD
Source: Amgen, Inc.
Amount: $25,000
Term: 1995-2002
Evaluation of Effects of CP-34,131 on Neutrophil Function
Principal Investigator: Daniel R. Ambruso, MD
Source: Pfizer, Inc.
Amount: $2,000/yr
Term: 2001-2012
General Studies of Neutrophil Function and Biochemistry
Principal Investigator: Daniel R. Ambruso, MD
Source: Bonfils Blood Center
Amount: $200,000
Term: 2001-2002
University of Colorado Cancer Center Core Grant - Pediatric Oncology
Principal Investigator: Paul Bunn, MD
Program Director for Pediatric Oncology: Robert L. Garcea, MD
Source: National Institutes of Health - CA46934-08
Amount: $1,610,750
Term: 1996-2001
Mechanisms in Papovavirus Assembly
Principal Investigator: Robert L. Garcea, MD
Source: National Institutes of Health - CA37667-16
Amount: $1,667,074
Term: 1997-2002
Microbial Pathogenesis and Host Responses to Infection
Principal Investigator: Randall K. Holmes, MD, PhD
Training Faculty: Robert L. Garcea, MD
Source: National Institutes of Health - CAI 07537
Amount: $380,515
Term: 1999-2004
Predoctoral Training Program in Molecular Biology
Principal Investigator: Charles McHenry, PhD
Training Faculty: Robert L. Garcea, MD
Source: National Institutes of Health - GM08730-01
Amount: $88,328
Term: 1999-2004
Postgraduate Training in Pediatric Oncology
Principal Investigator: Robert L. Garcea, MD
Source: National Institutes of Health, National Cancer Institute - CA8208601
Amount: $999,879
Term: 2000-2005
MEKK2 KO Defines Hematopoietic Cell Signal Function
Principal Investigator: Timothy P. Garrington, MD
Source: National Institutes of Health, National Cancer Institute, K08 Award (Mentored Clinical Scientist Development Award) - CA85276-03
Amount: $662,500
Term: 2000-2005
Children's Oncology Group
Principal Investigator: Roger Giller, MD
Source: University of Colorado, Department of Pediatrics
Amount: $175,640
Term: 1980-2003
Identification and Characterization of a Novel t(1:19) Translocation in Acute Lymphoblastic Leukemia
Principal Investigator: Lia Gore, MD
Source: Cancer League of Colorado
Amount: $45,438
Term: 1999-2001
K12 Clinical Oncology Scholars Award
Principal Investigator: Lia Gore, MD
Source: National Institutes of Health - CA86913
Amount: $871,500
Term: 2001-2008
Butterfly Program
Principal Investigator: Brian S. Greffe, MD
Source: Children's Hospice International Grant
Amount: $100,000
Term: 2002-2003
CE1160-3003 New IvIg for Pediatric ITP
Principal Investigator: Taru Hays, MD
Source: Aventis Behring LLC
Amount: $5,000 Per patient enrolled
Term: 2000-2002
Abnormal Hemoglobin Testing and Counseling Services
Principal Investigator: Kathryn L. Hassell, MD
Faculty: Rachelle Nuss, MD
Source: Wyoming Department of Health
Amount: $4,880
Term: 2001-2003
Sickle Cell Center Contract for Newborn Screening Follow-Up
Principal Investigator: Kathryn L. Hassell, MD
Faculty: Rachelle Nuss, MD
Source: Colorado Department of Health
Amount: $175,164
Term: 2001-2003
Teaching and Interpretation of Hemoglobin Electrophoresis
Principal Investigator: Kathryn L. Hassell, MD
Faculty: Rachelle Nuss, MD
Source: University of Colorado Hospital Laboratory
Amount: $10,000
Term: 2001-2003
Contract to Revise Mountain States/Texas Regional Sickle Cell Clinical Care Guidelines and Protocol
Principal Investigator: Peter A. Lane, MD
Source: Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Bureau
Amount: $24,838
Term: 2001-2002
Early Hearing Detection and Intervention: Tracking, Research and Integration with Other Newborn Screening Programs
Principal Investigator: Peter A. Lane, MD
Source: Centers for Disease Control and Prevention - 02-00556
Amount $115,000
Term: 2001-2004
Multicenter Investigation of Induction of Stable Mixed Chimerism after Bone Marrow Transplantation from HLA-Identical Donors for Sickle Cell Disease
Principal Investigator: Peter A. Lane, MD
Source: National Institutes of Health
Amount: $44,400
Term: 2001-2006
Regional Clinical Care Guidelines and Protocols to Improve Health Care Services for Infants and Children with Sickle Cell Disease in Colorado and Arizona
Principal Investigator: Peter A. Lane, MD
Source: SPRANS Maternal and Child Health Bureau
Amount: $344,632
Term: 2001-2002
Develop, Implement and Ensure Comprehensive Hemophilia Evaluation and Management of Clinics for Federal Region VIII
Principal Investigator: Marilyn Manco-Johnson, MD
Source: Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Bureau - MC00008-01
Amount: $499,684
Term: 2001-2003
Integrating Prevention Services for Persons with Bleed and Clotting Disorders
Principal Investigator: Marilyn Manco-Johnson, MD
Source: Centers for Disease Control and Prevention - CCU8200552-01
Amount: $184,441
Term: 2001-2003
Preventing Complications in Persons with Hemophilia (Mountain States Regional Hemophilia Center)
Principal Investigator: Marilyn Manco-Johnson, MD
Source: Centers for Disease Control and Prevention - CCU813109-06
Amount: $323,778
Term: 2001-2003
Prevention of Joint Disease in Preschool Children with Hemophilia
Principal Investigator: Marilyn Manco-Johnson, MD
Source: Centers for Disease Control and Prevention - CCU812106-07
Amount: $211,114
Term: 2001-2003
Provide Education, Community Outreach and Direct Patient Care for Hemophilia and Related Bleeding Disorders
Principal Investigator: Marilyn Manco-Johnson, MD
Source: State of Colorado
Amount: $231,625
Term: 2001-2003
Genetics of Inhibitor Formation in Hemophilia Development
Principal Investigator: Rachelle Nuss, MD
Source: National Institutes of Health - HL 61933
Amount: Per patient enrolled
Term: 2000-2001
rAHF for Surgery
Principal Investigator: Rachelle Nuss, MD
Source: Baxter Health Care Corporation
Amount: Per patient enrolled
Term: 2001
An Animal Model of TRALI
Principal Investigator: Christopher Silliman, MD, PhD
Source: National Institutes of Health - HL-59355-04
Amount: $180,531
Term: 1999-2003
Project IX: Lipid Chemistry CORE, PO-A: The Role of Lipids Generated during Blood Storage in Trauma-Induced Multiple Organ Failure
Principal Investigator: Christopher Silliman, MD, PhD
Source: National Institutes of Health
Term: 2001-2004
Trauma Primes Cells, Projects I and III
Principal Investigator: Christopher Silliman, MD, PhD
Source: National Institutes of Health
Amount: $144,045
Term: 1998-2001
1999-2000
An Open-Label, Non-Comparative Study of FK463 for the Treatment of Invasive Aspergillosis
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc
Amount: Per patient enrolled
Term: 1999-present
An Open-Label, Non-Comparative Study of FK463 in the treatment of Candidemia or Invasive Candidiasis
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc.
Amount: Per patient enrolled
Term: 1999-present
A Phase III, Randomized, Double-Blind, Comparative Trial of FK463 vs. Fluconazole for Prophylaxis of Fungal Infections in Patients Undergoing a Hematopoietic Stem Cell Transplant
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc
Amount: Per patient enrolled
Term: 1999-2001
A Phase I Study to Determine the Safety and Pharmacokinetics of FK463 in Febrile Neutropenic Pediatrics
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc.
Amount: Per patient enrolled
Term: 1999-2001
A Phase III, Double-Blind, Randomized Comparison of Two Administration Schedules of Leridistim (SC-70935) vs. G-CSF in the Prevention of Secondary Febrile Neutropenia in Pediatric Cancer Patients
Principal Investigator: Edythe A. Albano, MD
Source: GD Searle & CO
Amount: Per patient enrolled
Term: 1999-2001
A Phase II Study of SC-70935 in Pediatric Cancer Patients with Solid Tumors Receive Ifosfamide, Carboplatin, and Etoposide (ICE)
Principal Investigator: Edythe A. Albano, MD
Source: GD Searle & CO
Amount: Per patient enrolled
Term: 1999-2000
Evaluation of Neutrophil Function During Administration of G-CSF to Normal Volunteers
Principal Investigator: Daniel R. Ambruso, MD
Source: Amgen, Inc.
Amount: $25,000
Term: 1995-present
Evaluation of Stored Packed Red Cells on Neutrophil Activation and Viability
Principal Investigator: Daniel R. Ambruso, MD
Source: HemaSure
Amount: $8,000
Term: 2000
Evaluation of Effects of CP-34,131 on Neutrophil Function
Principal Investigator: Daniel R. Ambruso, MD
Source: Pfizer
Amount: $2,000/yr
Term: 1997-present
General Studies of Neutrophil Function and Biochemistry
Principal Investigator: Daniel R. Ambruso, MD
Source: Bonfils Blood Center
Amount: $200,000/yr
Term: 1979-present
Support of Brain Tumor Program
Principal Investigator: Nicholas Foreman, MD, ChB
Source: TriDelta
Amount: $19,000
Term: 1999
Abrogation of Immunosuppressive Gangliosides in Glioblastoma
Principal Investigator: Nicholas Foreman, MD, ChB
Source: National Cancer Foundation
Amount: $13,000
Term: 1998-1999
Study of Interaction Chemotherapy/Radiation in Glioblastoma: In Vitro Model
Principal Investigator: Nicholas Foreman, MD, ChB
Source: The Children's Hospital Cancer Center Chapter
Amount: $10,850
Term: 1998-1999
Mechanisms in Papovavirus Assembly
Principal Investigator: Robert L. Garcea, MD
Source: National Institutes of Health
Amount: $1,667,074
Term: 1997-2002
University of Colorado Cancer Center Core Grant - Pediatric Oncology
Principal Investigator: Paul Bunn, MD
Co-Investigator: Robert L. Garcea, MD
Source: National Institutes of Health
Amount: $1,610,750
Term: 1996-2001
Prevention of Cervical Cancer: An In Vivo Test of a New Papillomavirus Vaccine
Principal Investigator: Robert L. Garcea, MD
Source: Colorado Cancer Center
Amount: $19,735
Term: 2000
Microbial Pathogenesis and Host Responses to Infection
Principal Investigator: Randell K. Holmes, MD, PhD
Co-Investigator: Robert L. Garcea, MD
Source: National Institutes of Health
Amount: $76,103
Term: 1999-2004
Predoctoral Training Program in Molecular Biology
Principal Investigators: Charles McHenry, PhD and Robert L. Garcea, MD
Source: National Institutes of Health
Amount: $88,328
Term: 1999-2004
Postgraduate Training in Pediatric Oncology
Principal Investigator: Robert L. Garcea, MD
Source: National Institutes of Health
Amount: $188,332
Term: 2000-2005
Generating Neutralizing Antibodies Against Papillomaviruses
University of Colorado Cancer Center Core Grant - Pediatric Oncology
Principal Investigator: Robert L. Garcea, MD
Source: Colorado Cancer League
Amount: $25,500
Term: 1998-1999
MEKK2 KO Defines Hematopoietic Cell Signal Function
Principal Investigator: Timothy P. Garrington, MD
Source: National Institutes of Health, National Cancer Institute K08 Award (Mentored Clinical Scientist Development Award)
Amount: $124,500/yr
Term: 2000-2005
Use of Knockout of MEKK2 to Define its Role in Regulation of Signal Transduction Pathways in Cells of Hematopoietic Lineage
Principal Investigator: Timothy P. Garrington, MD
Source: University of Colorado Cancer Center, American Cancer Society Research Seed Grant
Amount: $10,000
Term: 1999-2000
CE1160-3003 New IvIg for Pediatric ITP
Principal Investigator: Taru Hays, MD
Source: Aventis Behring LLC
Amount: $5,000 Per patient
Term: 2000-2002
Fetal Stem Cell Transplantation for Alpha Thalassemia
University of Colorado Cancer Center Core Grant - Pediatric Oncology
Principal Investigator: Anthony R. Hayward, MD, PhD
Co-Investigator: Roger Giller, MD
Source: National Institutes of Health
Amount: $125,518/yr
Term: 1994-1999
Functional Analyses of the t(17;19)-ALL Chimera E2A-HLF
Principal Investigator: Stephen P. Hunger, MD
Source: American Cancer Society Research Project Grant
Amount: $300,000
Term: 1999-2002
Molecular Genetics of Relapsed Childhood ALL
Principal Investigator: Stephen P. Hunger, MD
Source: Leukemia and Lymphoma Society
Amount: $287,526
Term: 1998-2001
Identification of Genes Involved in Progression of Childhood ALL via Comparative Genomic Hybridization
Principal Investigator: Stephen P. Hunger, MD
Source: The Loewenstern Family Foundation
Amount: $37,500
Term: 1998-2001
Identification of Genes Involved in Variant (1;19) Translocations in Childhood ALL
Principal Investigator: Stephen P. Hunger, MD
Source: The Monfort Family Foundation
Amount: $142,500
Term: 1998-2001
Functional Analyses of the t(17;19)-ALL Chimera E2A-HLF
Principal Investigator: Stephen P. Hunger, MD
Source: National Cancer Institute Shannon Award
Amount: $40,000
Term: 1998-2000
Sickle Cell Center Contract for Newborn Screening Follow-up
Principal Investigator: Peter A. Lane, MD
Source: Colorado Department of Health
Amount: $83,225/yr
Term: 1987-2001
Abnormal Hemoglobin Testing and Counseling Services
Principal Investigator: Peter A. Lane, MD
Source: Wyoming Department of Health
Amount: $2,440/yr
Term: 1991-2001
Teaching and Interpretation of Hemoglobin Electrophoresis
Principal Investigator: Peter A. Lane, MD
Source: University Hospital Laboratory
Amount: $5,000/yr
Term: 1993-2001
Regional Clinical Care Guidelines and Protocols to Improve Health Care Services for Infants and Children with Sickle Cell Disease in Colorado and Arizona
Principal Investigator: Peter A. Lane, MD
Source: SPRANS Maternal and Child Health Bureau
Amount: $344,632/yr
Term: 1997-2001
Joint Outcome in Hemophilia
Principal Investigators: Marilyn Manco-Johnson, MD and Rachelle Nuss, MD
Source: Centers for Disease Control and Prevention
Amount: $550,000/yr
Term: 1995-2000
Hemophilia Surveillance
Principal Investigator: Rachelle Nuss, MD
Source: Centers for Disease and Control Prevention
Amount: $128,339/yr
Term: 1996-1999
Identification and Characterization of a Novel t(1:19) Translocation in Acute Lymphoblastic Leukemia
Principal Investigator: Lia Gore, MD
Source: Cancer League of Colorado
Amount: $45,438
Term: 1999-2001
Identification and Characterization of a Novel t(1:19) Translocation in Childhood Acute Lymphoblastic Leukemia
Principal Investigator: Lia Gore, MD
Source: Leukemia Research Foundation
Amount: $25,000
Term: 1999-2000
Immunologic Reconstitution Following BMT
Principal Investigator: Ralph Quinones, MD
Source: The Children's Hospital Cancer Volunteers
Amount: $10,000
Term: 1998-1999
Trauma Primes Cells, Project I and III
Principal Investigator: Christopher Silliman, MD, PhD
Source: National Institutes of Health
Term: 1998-2001
Professional Development Award
Principal Investigator: Christopher Silliman, MD, PhD
Source: The Children's Hospital Research Institute
Term: 1998-1999
An Animal Model of TRALI
Principal Investigator: Christopher Silliman, MD, PhD
Source: National Institutes of Health
Term: 1999-2003
The Pathophysiology of Transfusion Related Acute Lung Injury in an Animal Model and In Vitro - Investigation of Endothelium as an Active Participant
Principal Investigator: Christopher Silliman, MD, PhD
Source: National Blood Foundation
Amount: $30,000
Term: 1997-1999
Intracellular RBC Pharmacokinetics of Thiopurines in ALL
Principal Investigator: Gary Erdmann, MD
Consultant to Grant: Linda Stork, MD
Source: National Cancer Institute Research Grant
Term: 1997-2000
Children's Oncology Group
Principal Investigators: Linda Stork, MD (2001-present);
Lorrie Odom, MD (1980-2000)
Source: University of Colorado, Department of Pediatrics
Amount: $175,640/yr
Term: 1980-2003
|
|
